CompletedNot Applicable

The Role of IGRA in Screening and Monitoring for TB During Anti TNF Therapy in Patients With IMID

Hong Kong9,160 participantsStarted 2012-03

Plain-language summary

Hong Kong is a region of intermediate TB burden, and the reactivation of latent TB in IMID patients treated with anti-TNF can be a serious problem. This study aims to investigate the role of IGRA in screening for latent TB in IBD patients and control subjects. In part II of the study, patients of other immune-mediated inflammatory diseases (IMID) will also be included to investigate the role of serial interferon-gamma release assays (IGRA) for the diagnosis of tuberculosis (TB) infection in patients with immune-mediated inflammatory diseases (IMID) treated with biologics

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients aged 18 years or older * patients with a diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) for at least 3 months defined by histology or radiology Exclusion Criteria: * Patients with a previous history of TB * Patients with a positive IGRA or CXR suggesting latent tuberculosis prior to commencement of therapy

What they're measuring

IGRA positivity

Timeframe: 2 Years

IGRA conversion

Timeframe: 3 Years

Trial details

NCT IDNCT02135289

SponsorChinese University of Hong Kong

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-07-31

View on ClinicalTrials.gov More Inflammatory Bowel Disease trials